Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...

Related Keywords

Boston ,Massachusetts ,United States ,Ian Stone ,Marcio Souza ,Exchange Commission ,Nasdaq ,Facebook ,Twitter ,Linkedin ,Canale Communications ,Praxis Precision Medicines Inc ,Drug Administration ,Globenewswire Inc ,Precision Medicines ,Business Highlights ,Upcoming Milestones ,Small Molecule ,Daily Living ,Antisense Oligonucleotide ,License Agreement ,Praxi Cerebrum ,Praxi Solidus ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Although Praxi ,Markets ,